CGTX COGNITION THERAPEUTICS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1455365 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY42.9%
TTM EPS YoY66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-48.6%
ROA-40.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets15.9%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $37.19M | $41.68M |
| SG&A expense | $10.61M | $12.29M |
| Operating income | -$47.80M | -$53.97M |
| Pretax income | $23.49M | $33.97M |
| Income tax | $0 | $0 |
| Net income | -$23.49M | -$33.97M |
| EBITDA | -$47.76M | -$53.86M |
| EPS (basic) | -0.32 | -0.86 |
| EPS (diluted) | -0.32 | -0.86 |
| Weighted avg. shares (diluted) | 72.77M | 39.73M |
| Balance sheet | ||
| Cash & equivalents | $36.81M | $25.01M |
| Current assets | $47.99M | $29.55M |
| PP&E, net | $93,000 | $181,000 |
| Total assets | $48.39M | $30.23M |
| Current liabilities | $13.92M | $11.14M |
| Total liabilities | $14.12M | $11.48M |
| Shareholders' equity | $34.27M | $18.75M |
| Shares outstanding | 88.90M | 59.85M |
| Cash flow statement | ||
| Operating cash flow | -$24.59M | -$28.47M |
| Capital expenditure | — | $4,000 |
| Free cash flow | — | -$28.48M |
| Investing cash flow | $9,000 | -$4,000 |
| Financing cash flow | $36.57M | $23.57M |
| Depreciation & amortization | $36,000 | $107,000 |
| Stock-based compensation | $2.09M | $3.75M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.